The Pulse
Tempus Wins FDA Clearance for ECG-Based Mitral-Regurgitation Detection
Tempus AI received FDA 510(k) clearance for ECG-MR, software that flags signs associated with moderate or severe mitral regurgitation from standard resting ECGs. The tool is intended for at-risk patients 65 and older and is not a stand-alon
AI.info Team · Written with AI · fact-checked ·
Tempus AI received FDA 510(k) clearance on September 28 for software that analyzes standard resting electrocardiograms to flag signs associated with moderate or severe mitral regurgitation, a condition in which blood leaks backward through the heart’s mitral valve. The product, called ECG-MR, is designed to help clinicians identify at-risk patients for further evaluation, such as diagnostic imaging—not to confirm the condition on its own.
ECG-MR adds a fourth cardiac product
The clearance makes ECG-MR the fourth FDA-cleared product in Tempus’ ECG-AI portfolio. The portfolio spans arrhythmia, heart function, pulmonary vascular disease and valvular disease. The new clearance extends the company’s effort to extract information about cardiovascular risk from a test already used in routine care.
“A standard ECG contains far more information than we have traditionally been able to use,” said Brandon Fornwalt, Tempus’ senior vice president of cardiology. The product line is intended to help clinicians gain more actionable information from ECGs, he said.
Who the software is intended to assess
ECG-MR is intended for clinical, non-ambulatory 12-lead ECG recordings collected at a healthcare facility from patients 65 or older who are at risk of cardiovascular disease. The company lists coronary artery disease, hypertension, obesity and diabetes among relevant risk factors; symptoms such as shortness of breath, chest pain or swelling in the legs may also be relevant. The indicated patients must not have had prior mitral-valve intervention or a previous diagnosis of moderate or severe mitral regurgitation.
The software analyzes ECG data and returns a binary result for interpretation. It is not intended as a stand-alone diagnostic tool, for serial patient monitoring, or for ECGs with paced rhythms. Clinicians should interpret results alongside the original ECG, other tests, symptoms and clinical history, according to Tempus.
A flag for follow-up, not a diagnosis
Mitral regurgitation can go undetected because early disease may produce no symptoms or symptoms that are not specific to the condition. Tempus positions ECG-MR as an early-detection aid that can help identify patients who may warrant additional assessment. The announcement does not provide accuracy figures or other performance results for the product.
The distinction matters: the system looks for signs associated with the condition in an ECG, while further clinical evaluation is needed to assess a patient. Its intended use is also limited to a defined group—patients at least 65 years old with cardiovascular risk, without a prior moderate or severe diagnosis or mitral-valve intervention.
Tempus expands its ECG screening portfolio
ECG-MR joins Tempus’ other cleared ECG-AI products in a portfolio that now reaches from rhythm and heart-function signals to pulmonary vascular and valve disease. The company’s announcement frames the products as tools for surfacing risk from routine ECG recordings. For ECG-MR, the concrete next step remains referral for further evaluation when clinicians consider the result alongside a patient’s history and other diagnostic information.